GlassScriptPhysician profile
Gerard Brophy Chamberlin
NPI 1750503124
$1,885.51
in general payments reported to CMS, 2019-2025
24 companies · $41.08 in 2025
The $41.08 reported for 2025 was less than what a typical Internal Medicine provider received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,199 · 2020: $241 · 2021: $126 · 2023: $111 · 2024: $168 · 2025: $41.08.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $300 · Long Term Medical Supply Or Device Loan: $19.98.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $300.09 |
| Long Term Medical Supply Or Device Loan | $19.98 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boehringer Ingelheim Pharmaceuticals, INC. | $214.96 | 2019-2023 | |
| Astrazeneca Pharmaceuticals LP | $193.88 | 2019-2021 | |
| Sanofi-Aventis U.S. LLC | $190.13 | 2019 | |
| Glaxosmithkline, LLC. | $181.29 | 2019-2024 | Trelegy Ellipta |
| Sunovion Pharmaceuticals INC. | $140.79 | 2019-2020 | |
| Regeneron Healthcare Solutions, INC. | $138.89 | 2024 | Evkeeza |
| Astellas Pharma US INC | $124.13 | 2019-2025 | Veozah |
| Novo Nordisk INC | $93.27 | 2019-2020 | |
| Amgen INC. | $90.56 | 2019-2023 | Repatha, Otezla |
| Lilly USA, LLC | $83.55 | 2019-2020 | |
| Merck Sharp & Dohme LLC | $72.31 | 2019-2023 | Gardasil 9, Vaxneuvance, M-M-R II |
| Pfizer INC. | $55.28 | 2019 | |
| Takeda Pharmaceuticals U.S.A., INC. | $46.33 | 2019 | |
| Janssen Pharmaceuticals, INC | $43.27 | 2019 | |
| Otsuka America Pharmaceutical, INC. | $42.44 | 2019-2023 | Rexulti |
Show all 24 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Seqirus USA INC | $27.83 | 2019 | |
| Novartis Pharmaceuticals Corporation | $27.12 | 2019 | |
| Abbvie INC. | $21.65 | 2023 | Vraylar |
| Abbott Laboratories | $19.98 | 2025 | Freestyle Insulinx |
| Philips North America LLC | $17.62 | 2019 | |
| Circassia INC. | $16.43 | 2019 | |
| Teva Pharmaceuticals USA, INC. | $16.02 | 2019 | |
| Lundbeck LLC | $14.27 | 2024 | Rexulti |
| Sanofi Pasteur INC. | $13.51 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Gerard Chamberlin listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.